A citation-based method for searching scientific literature


List of co-cited articles
131 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers.
Jie Ling, Kim A Johnson, Zhuang Miao, Ashok Rakhit, Michael P Pantze, Marta Hamilton, Bert L Lum, Chandra Prakash. Drug Metab Dispos 2006
167
35



Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma.
Johannes J M Rood, Mark T J van Bussel, Jan H M Schellens, Jos H Beijnen, Rolf W Sparidans. J Chromatogr B Analyt Technol Biomed Life Sci 2016
31
25

A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry.
Nielka P van Erp, Djoeke de Wit, Henk-Jan Guchelaar, Hans Gelderblom, Trees J Hessing, Jan den Hartigh. J Chromatogr B Analyt Technol Biomed Life Sci 2013
57
25

A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma.
Lionel Faivre, Charline Gomo, Olivier Mir, Fabrice Taieb, Audrey Schoemann-Thomas, Stanislas Ropert, Michel Vidal, Daniel Dusser, Alain Dauphin, Francois Goldwasser,[...]. J Chromatogr B Analyt Technol Biomed Life Sci 2011
48
25


Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer.
Hideki Hayashi, Yutaro Kita, Hirotoshi Iihara, Koumei Yanase, Yasushi Ohno, Chiemi Hirose, Maya Yamada, Kenichiro Todoroki, Kiyoyuki Kitaichi, Shinya Minatoguchi,[...]. Biomed Chromatogr 2016
28
25

An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients.
Yi Zhen, Audrey Thomas-Schoemann, Lilia Sakji, Pascaline Boudou-Rouquette, Nicolas Dupin, Laurent Mortier, Michel Vidal, Francois Goldwasser, Benoit Blanchet. J Chromatogr B Analyt Technol Biomed Life Sci 2013
27
20

Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS.
Stéphane Bouchet, Emmanuelle Chauzit, Dominique Ducint, Nadège Castaing, Mireille Canal-Raffin, Nicholas Moore, Karine Titier, Mathieu Molimard. Clin Chim Acta 2011
119
20

Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.
Huixin Yu, Neeltje Steeghs, Cynthia M Nijenhuis, Jan H M Schellens, Jos H Beijnen, Alwin D R Huitema. Clin Pharmacokinet 2014
153
20

Simultaneous Determination of Celecoxib, Erlotinib, and its Metabolite Desmethyl-Erlotinib (OSI-420) in Rat Plasma by Liquid chromatography/Tandem Mass Spectrometry with Positive/Negative Ion-Switching Electrospray Ionisation.
Satheeshmanikandan R S Thappali, Kanthikiran Varanasi, Sridhar Veeraraghavan, Rambabu Arla, Sandhya Chennupati, Madheswaran Rajamanickam, Swaroop Vakkalanka, Mukkanti Khagga. Sci Pharm 2012
11
36

Quantitative determination of erlotinib and O-desmethyl erlotinib in human EDTA plasma and lung tumor tissue.
N A G Lankheet, E E Schaake, H Rosing, J A Burgers, J H M Schellens, J H Beijnen, A D R Huitema. Bioanalysis 2012
9
44

Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes.
Jing Li, Ming Zhao, Ping He, Manuel Hidalgo, Sharyn D Baker. Clin Cancer Res 2007
239
20

Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer.
Kathryn Brown, Craig Comisar, Han Witjes, John Maringwa, Rik de Greef, Karthick Vishwanathan, Mireille Cantarini, Eugène Cox. Br J Clin Pharmacol 2017
64
20

Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs.
M Herbrink, N de Vries, H Rosing, A D R Huitema, B Nuijen, J H M Schellens, J H Beijnen. Biomed Chromatogr 2018
31
20

Quantification of afatinib, alectinib, crizotinib and osimertinib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry; focusing on the stability of osimertinib.
G D Marijn Veerman, Mei H Lam, Ron H J Mathijssen, Stijn L W Koolen, Peter de Bruijn. J Chromatogr B Analyt Technol Biomed Life Sci 2019
26
20

High throughput routine determination of 17 tyrosine kinase inhibitors by LC-MS/MS.
Camille Merienne, Marine Rousset, Dominique Ducint, Nadège Castaing, Karine Titier, Mathieu Molimard, Stéphane Bouchet. J Pharm Biomed Anal 2018
55
20

Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.
Rafael Reis, Laurence Labat, Marie Allard, Pascaline Boudou-Rouquette, Jeanne Chapron, Audrey Bellesoeur, Audrey Thomas-Schoemann, Jennifer Arrondeau, Frédérique Giraud, Jérôme Alexandre,[...]. J Pharm Biomed Anal 2018
34
20

Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer.
Jian-Feng Lu, Steve M Eppler, Julie Wolf, Marta Hamilton, Ashok Rakhit, Rene Bruno, Bert L Lum. Clin Pharmacol Ther 2006
180
20

An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry.
L Couchman, M Birch, R Ireland, A Corrigan, S Wickramasinghe, D Josephs, J Spicer, R J Flanagan. Anal Bioanal Chem 2012
53
15


A method to quantify several tyrosine kinase inhibitors in plasma by micellar liquid chromatography and validation according to the European Medicines Agency guidelines.
Iris Garrido-Cano, Aurelio García-García, Juan Peris-Vicente, Enrique Ochoa-Aranda, Josep Esteve-Romero. Talanta 2015
18
16


Liquid chromatography-tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma.
Rolf W Sparidans, Seng Chuan Tang, Luan N Nguyen, Alfred H Schinkel, Jan H M Schellens, Jos H Beijnen. J Chromatogr B Analyt Technol Biomed Life Sci 2012
16
18

Metabolism and disposition of oral dabrafenib in cancer patients: proposed participation of aryl nitrogen in carbon-carbon bond cleavage via decarboxylation following enzymatic oxidation.
David A Bershas, Daniele Ouellet, Donna B Mamaril-Fishman, Noelia Nebot, Stanley W Carson, Samuel C Blackman, Royce A Morrison, Jerry L Adams, Kristen E Jurusik, Dana M Knecht,[...]. Drug Metab Dispos 2013
34
15

Simultaneous quantification of ruxolitinib and nilotinib in rat plasma by LC-MS/MS: application to a pharmacokinetic study.
Sridhar Veeraraghavan, Satheeshmanikandan Thappali, Srikant Viswanadha, Sandhyarani Chennupati, Santhoshkumar Nalla, Manikantakumar Golla, Swaroopkumar Vakkalanka, Manivannan Rangasamy. J Pharm Biomed Anal 2014
12
25

HPLC-DAD protein kinase inhibitor analysis in human serum.
Marek Dziadosz, Rüdiger Lessig, Heidemarie Bartels. J Chromatogr B Analyt Technol Biomed Life Sci 2012
23
15

Liquid chromatography-tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid-liquid extraction.
Rolf W Sparidans, Stephanie van Hoppe, Johannes J M Rood, Alfred H Schinkel, Jan H M Schellens, Jos H Beijnen. J Chromatogr B Analyt Technol Biomed Life Sci 2016
15
20

Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma.
Lutz Götze, Axel Hegele, Stephan Klaus Metzelder, Harald Renz, Wolfgang Andreas Nockher. Clin Chim Acta 2012
67
15

Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.
Masahide Fukudo, Yasuaki Ikemi, Yosuke Togashi, Katsuhiro Masago, Young Hak Kim, Tadashi Mio, Tomohiro Terada, Satoshi Teramukai, Michiaki Mishima, Ken-Ichi Inui,[...]. Clin Pharmacokinet 2013
66
15


Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry.
R Honeywell, K Yarzadah, E Giovannetti, N Losekoot, E F Smit, M Walraven, J S W Lind, C Tibaldi, H M Verheul, G J Peters. J Chromatogr B Analyt Technol Biomed Life Sci 2010
65
15

Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry.
Ling-Zhi Wang, Michelle Yi-Xiu Lim, Tan-Min Chin, Win-Lwin Thuya, Pei-Ling Nye, Andrea Wong, Sui-Yung Chan, Boon-Cher Goh, Paul C Ho. J Chromatogr B Analyt Technol Biomed Life Sci 2011
21
15

Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature.
Emilie Petit-Jean, Thierry Buclin, Monia Guidi, Elisabeth Quoix, Bénédicte Gourieux, Laurent A Decosterd, Anne-Cécile Gairard-Dory, Geneviève Ubeaud-Séquier, Nicolas Widmer. Ther Drug Monit 2015
29
15

Development and Validation of a Simultaneous Quantification Method of 14 Tyrosine Kinase Inhibitors in Human Plasma Using LC-MS/MS.
Huu H Huynh, Claire Pressiat, Hélène Sauvageon, Isabelle Madelaine, Patricia Maslanka, Céleste Lebbé, Catherine Thieblemont, Lauriane Goldwirt, Samia Mourah. Ther Drug Monit 2017
54
15

Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor.
Erin R Lepper, Sandra M Swain, Antoinette R Tan, William D Figg, Alex Sparreboom. J Chromatogr B Analyt Technol Biomed Life Sci 2003
35
15

Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry.
Ming Zhao, Ping He, Michelle A Rudek, Manuel Hidalgo, Sharyn D Baker. J Chromatogr B Analyt Technol Biomed Life Sci 2003
50
15

The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry.
Andrea R Masters, Christopher J Sweeney, David R Jones. J Chromatogr B Analyt Technol Biomed Life Sci 2007
31
15

Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor.
Paul A Dickinson, Mireille V Cantarini, Jo Collier, Paul Frewer, Scott Martin, Kathryn Pickup, Peter Ballard. Drug Metab Dispos 2016
72
15

The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.
Ashok Rakhit, Michael P Pantze, Scott Fettner, Hannah M Jones, Jean-Eric Charoin, Myriam Riek, Bert L Lum, Marta Hamilton. Eur J Clin Pharmacol 2008
92
15

Effects of smoking on the pharmacokinetics of erlotinib.
Marta Hamilton, Julie L Wolf, Jason Rusk, Shannon E Beard, Gary M Clark, Karsten Witt, Pablo J Cagnoni. Clin Cancer Res 2006
231
15



A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma.
J F Grippo, W Zhang, D Heinzmann, K H Yang, J Wong, A K Joe, P Munster, N Sarapa, A Daud. Cancer Chemother Pharmacol 2014
39
10

Development and validation of a rapid and simple LC-MS/MS method for quantification of vemurafenib in human plasma: application to a human pharmacokinetic study.
Kevin Bihan, Chloé Sauzay, Lauriane Goldwirt, Fanny Charbonnier-Beaupel, Jean-Sebastien Hulot, Christian Funck-Brentano, Noël Zahr. Ther Drug Monit 2015
7
28

Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma.
Rolf W Sparidans, Selvi Durmus, Alfred H Schinkel, Jan H M Schellens, Jos H Beijnen. J Chromatogr B Analyt Technol Biomed Life Sci 2012
16
12

A LC/MS/MS micro-method for human plasma quantification of vemurafenib. Application to treated melanoma patients.
Jean-Claude Alvarez, Elisa Funck-Brentano, Emuri Abe, Isabelle Etting, Philippe Saiag, Adeline Knapp. J Pharm Biomed Anal 2014
14
14

The role of BRAF V600 mutation in melanoma.
Paolo A Ascierto, John M Kirkwood, Jean-Jacques Grob, Ester Simeone, Antonio M Grimaldi, Michele Maio, Giuseppe Palmieri, Alessandro Testori, Francesco M Marincola, Nicola Mozzillo. J Transl Med 2012
383
10

Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient.
Nienke A G Lankheet, Christian U Blank, Henk Mallo, Sandra Adriaansz, Hilde Rosing, Jan H M Schellens, Alwin D R Huitema, Jos H Beijnen. J Anal Toxicol 2011
25
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.